Diligence memo · auto-generated · as of July 2, 2026

Pharmaca Integrative Pharmacy Inc

Pharmaca Integrative Pharmacy Inc looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Pharmaca Integrative Pharmacy Inc operates in Biotech / Pharma, based in BOULDER.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Pharmaca Integrative Pharmacy Inc has raised $14M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $7.0M on 2017-01-31.

Most recent recorded round closed around 2017-01-31.

Valuation (modeled)modeled

Provath models Pharmaca Integrative Pharmacy Inc at approximately $235M (range $7.8M–$1.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.08× the median modeled value of Series A Biotech / Pharma companies in 2016–2018 (5 peers) — value vs value, same stage and era. Within the normal band (108% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 47 months.

Last raise 9.4 yr ago; this sector typically re-raises about every 15 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 1.1× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 67% of Biotech / Pharma peers (227 compared).

Modeled value ranks above 81% of those peers.

Closest niche peers: Oncoheroes Biosciences Inc., PharmacoPhotonics, Inc., Key Biologics Holdings, LLC, Swift Biosciences, Inc..

Peoplefiled

17 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.